ADT use not linked to dementia in prostate cancer

ADT use not linked to dementia in prostate cancer

(HealthDay)—For men with prostate cancer, use of androgen deprivation therapy (ADT) seems not to be associated with dementia, according to a study published online Nov. 21 in the Journal of Clinical Oncology.

Farzin Khosrow-Khavar, Ph.D., from McGill University in Hamilton, Canada, and colleagues examined whether use of ADT is associated with increased risk of dementia, including Alzheimer's disease. A cohort of 30,903 men newly diagnosed with nonmetastatic from April 1, 1988, to April 30, 2015 were recruited and followed until April 30, 2016. To account for delays associated with and minimize reverse causality, ADT exposure was lagged by one year.

The researchers found that 799 patients were newly diagnosed with dementia during a mean follow-up of 4.3 years (incidence, 6.0 per 1,000 person-years). ADT use was not associated with increased risk of dementia compared with nonuse (incidence, 7.4 versus 4.4 per 1,000 person-years; adjusted hazard ratio, 1.02; 95 percent confidence interval, 0.87 to 1.19). Cumulative duration of use and no single type of ADT correlated with increased risk of dementia in secondary analyses.

"In this population-based study, the use of ADT was not associated with an increased risk of ," the authors write. "Additional studies in different settings are needed to confirm these findings."

Explore further

Is androgen deprivation therapy for prostate cancer associated with dementia?

More information: Full Text
Journal information: Journal of Clinical Oncology

Copyright © 2016 HealthDay. All rights reserved.

Citation: ADT use not linked to dementia in prostate cancer (2016, November 28) retrieved 29 January 2022 from
This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.

Feedback to editors